1-methyl-3-[(3-methyl-2H-imidazol-1-yl)methyl]-2H-imidazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 1-methyl-3-[(3-methyl-2H-imidazol-1-yl)methyl]-2H-imidazole
• 化学式: C₉H₁₆N₄
• 分子量: 180.253
• InChiKey: OOPALQFAVZENDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  13
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-methyl-3-[(3-methyl-2H-imidazol-1-yl)methyl]-2H-imidazole 在 potassium carbonate 、 sulfur 作用下， 以 甲醇 为溶剂， 生成 bis(1-methyl-imidazole-2-thione)methane
  参考文献：
  名称：

  N，N'-聚乙烯基-桥咪唑-2-硫酮和苯并咪唑-2-硫酮的合成及配体性质

  摘要：

  已经制备了一系列N，N′-多亚甲基桥连的咪唑-和苯并咪唑-2-硫酮，该桥含有1至6个亚甲基，前者是通过N，甲基-咪唑被α，ω-二溴代烷烃烷基化然后再进行硫代反应而制得的。首先用磷酰氯处理，然后用硫脲处理。桥联的苯并咪唑硫酮与汞，钯和铜盐形成络合物，但与铁，钴，镍，锌，铂，镉，银或th形成络合物。咪唑硫酮与铁，钴，镍，铜，锌，锡，镉，钯，铂和银盐络合。

  DOI：

  10.1016/s0040-4020(01)80463-4
• 作为产物：
  描述：

  N-甲基咪唑 、 二溴甲烷 以 乙酸乙酯 为溶剂， 反应 1.0h， 生成 1-methyl-3-[(3-methyl-2H-imidazol-1-yl)methyl]-2H-imidazole
  参考文献：
  名称：

  N，N'-聚乙烯基-桥咪唑-2-硫酮和苯并咪唑-2-硫酮的合成及配体性质

  摘要：

  已经制备了一系列N，N′-多亚甲基桥连的咪唑-和苯并咪唑-2-硫酮，该桥含有1至6个亚甲基，前者是通过N，甲基-咪唑被α，ω-二溴代烷烃烷基化然后再进行硫代反应而制得的。首先用磷酰氯处理，然后用硫脲处理。桥联的苯并咪唑硫酮与汞，钯和铜盐形成络合物，但与铁，钴，镍，锌，铂，镉，银或th形成络合物。咪唑硫酮与铁，钴，镍，铜，锌，锡，镉，钯，铂和银盐络合。

  DOI：

  10.1016/s0040-4020(01)80463-4

文献信息

• MULTIMETALLIC ASSEMBLY, METHODS OF MAKING MULTIMETALLIC ASSEMBLY, METHODS OF OXIDIZING WATER, METHODS OF O-ATOM TRANSFER CATALYSTS, AND METHODS OF CARBON DIOXIDE REDUCTION
  申请人：UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

  公开号：US20130287671A1

  公开（公告）日：2013-10-31

  Embodiments of the present disclosure provide for multimetallic assemblies, methods of making a multimetallic assembly, methods of oxidizing water, methods of O-atom transfer catalysis, and the like.

  本公开的实施例提供了多金属组装体、制造多金属组装体的方法、氧化水的方法、O-原子转移催化的方法等。
• Metal complexes of N-heterocyclic carbenes as radiopharmaceuticals and antibiotics
  申请人：Youngs Wiley

  公开号：US20070021401A1

  公开（公告）日：2007-01-25

  A method for inhibiting microbial growth comprises administering an effective amount of a silver complex of a N-heterocyclic amine. A method for treating cancer cells or a method for imaging one or more tissues of a patient includes administering an effective amount of a complex of a N-heterocyclic amine and a radioactive metal. A method for treating urinary tract infections utilizing silver complexes of N-heterocyclic carbenes. N-heterocyclic carbenes of the present invention may be represented by the formula wherein Z is a heterocyclic group, and R 1 and R 2 are, independently or in combination, hydrogen or a C 1 -C 12 organic group selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heterocyclic, and alkoxy groups and substituted derivatives thereof.

  一种抑制微生物生长的方法包括给予有效量的N-杂环胺的银络合物。一种治疗癌细胞或成像患者一个或多个组织的方法包括给予有效量的N-杂环胺和放射性金属的络合物。一种利用N-杂环卡宾银络合物治疗尿路感染的方法。本发明的N-杂环卡宾可以用以下式表示，其中Z是杂环基，而R1和R2是独立或组合的氢或选择自烷基、环烷基、烯基、环烯基、炔基、芳基、芳基烷基、烷基芳基、杂环和烷氧基和其取代衍生物的C1-C12有机基。
• Metal Complexes of N-Heterocyclic Carbenes as Radiopharmaceuticals and Antibiotics
  申请人：Youngs Wiley J.

  公开号：US20080267867A1

  公开（公告）日：2008-10-30

  A method for inhibiting microbial growth comprises administering an effective amount of a silver complex of a N-heterocyclic amine. A method for treating cancer cells or a method for imaging one or more tissues of a patient includes administering an effective amount of a complex of a N-heterocyclic amine and a radioactive metal. N-heterocyclic carbenes of the present invention may be represented by formula (I) wherein Z is a heterocyclic group, and R 1 and R 2 are, independently or in combination, hydrogen or a C 1 -C 12 organic group selected from the group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heterocyclic, and alkoxy groups and substituted derivatives thereof.

  一种抑制微生物生长的方法包括给予一种N-杂环胺的银络合物有效量。一种治疗癌细胞或成像患者的一个或多个组织的方法包括给予一种N-杂环胺和放射性金属的络合物有效量。本发明的N-杂环卡宾可以用式(I)表示，其中Z是一个杂环基团，R1和R2独立或组合地是氢或C1-C12有机基团，所述有机基团选自烷基，环烷基，烯基，环烯基，炔基，芳基，芳基烷基，烷基芳基，杂环和其取代衍生物。
• Cytotoxic properties of rhenium(<scp>i</scp>) tricarbonyl complexes of N-heterocyclic carbene ligands
  作者：Nuchareenat Wiratpruk、Guneet K. Bindra、Alex Hamilton、Mark D. Hulett、Peter J. Barnard

  DOI：10.1039/d2dt00447j

  日期：——

  A family of eight rhenium(I) tricarbonyl complexes bearing pyridyl-imidazolylidene or bis-imidazolylidene ligands in combination with a series of N-acetyl amino acids ligands (glycine, isoleucine, and proline) and an acetate have been synthesised and characterised. These complexes are of interest as potential anticancer agents, where the oxygen bound carboxylate ligand can exchange with water giving

  已经合成并表征了带有吡啶基-咪唑亚基或双-咪唑亚基配体与一系列N-乙酰氨基酸配体（甘氨酸、异亮氨酸和脯氨酸）和乙酸盐的八种铼 ( I ) 三羰基配合物家族。这些复合物作为潜在的抗癌剂是令人感兴趣的，其中氧结合的羧酸盐配体可以与水交换，从而产生细胞毒性阳离子复合物。使用1 H NMR 时程实验评估了配合物的准一级水化速率常数，对于双咪唑亚基配体的配合物，平均k 1值为 6.22 × 10 -5 s -1而对于吡啶基-咪唑亚基配体，水合速率较慢，平均k 1值为3.00 × 10 -5 s -1。对三种癌细胞系（MDA-MB-231、PC3 和 HEPG2）的细胞毒性研究表明，双咪唑亚基配体的 Re( I ) 复合物比吡啶基-咪唑亚基配体的毒性显着更高。
• METAL COMPLEXES OF N-HETEROCYCLIC CARBENES
  申请人：YOUNGS Wiley J.

  公开号：US20110086830A1

  公开（公告）日：2011-04-14

  The present invention generally relates to metal complexes of N-heterocyclic carbenes that contain one or more additional active moieties and/or groups therein. In one embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with one or more additional active moieties and/or groups selected from fluoroquinolone compounds or derivatives thereof; steroids or derivatives thereof; anti-inflammatory compounds or derivatives thereof; anti-fungal compounds or derivatives thereof; anti-bacterial compounds or derivatives thereof; antagonist compounds or derivatives thereof; H 2 receptor compounds or derivatives thereof; chemotherapy compounds or derivatives thereof; tumor suppressor compounds or derivatives thereof; or C 1 to C 16 alkyl heteroatom groups where the heterotatom is selected from S, O, or N. In still another embodiment, the present invention relates to metal complexes of N-heterocyclic carbenes that contain an anti-fungal and/or anti-microbial moiety and/or group in combination with two or more additional active moieties and/or groups selected from fluoroquinolone compounds or derivatives thereof; steroids or derivatives thereof; anti-inflammatory compounds or derivatives thereof; anti-fungal compounds or derivatives thereof; anti-bacterial compounds or derivatives thereof; antagonist compounds or derivatives thereof; H 2 receptor compounds or derivatives thereof; chemotherapy compounds or derivatives thereof; tumor suppressor compounds or derivatives thereof; or C 1 to C 16 alkyl heteroatom groups where the heterotatom is selected from S, O, or N.